KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Income from Continuing Operations for 7 consecutive years, with 355913000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 6.45% to 355913000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1324192000.0 through Dec 2025, changed 0.5% year-over-year, with the annual reading at 1324192000.0 for FY2025, 0.5% changed from the prior year.
  • Income from Continuing Operations hit 355913000.0 in Q4 2025 for Royalty Pharma, down from 444211000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 806755000.0 in Q2 2021 to a low of 610030000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 291317900.0 across 5 years, with a median of 278073500.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 1236.61% in 2022 and later soared 10243.53% in 2025.
  • Year by year, Income from Continuing Operations stood at 53671000.0 in 2021, then tumbled by 1236.61% to 610030000.0 in 2022, then soared by 217.63% to 717586000.0 in 2023, then plummeted by 53.41% to 334351000.0 in 2024, then grew by 6.45% to 355913000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RPRX at 355913000.0 in Q4 2025, 444211000.0 in Q3 2025, and 90635000.0 in Q2 2025.